Company profile
Regenicin, Inc.
OTC: RGIN · Healthcare · Biotechnology
PublicHQ Little Falls, NJCIK 0001412659Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 31
v0.1 · 5/100 weight · pillars only
↑ listing tenure, Altman-Z · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$877.1k
Employees
3
as of 2026-08-29
Market cap
$15.3k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$877.1k-$877.1k2021
Operating income-$842.4k-$842.4k2021
Total assets$4.6k$4.6k2021
Liabilities$4.4M$4.4M2014
Equity-$5.2M-$5.2M2021
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Regenicin, Inc.’s financial profile?
Regenicin, Inc. earned -$877.1k in FY2021 net income.
Peers · Healthcare
MabCure Inc.——Parallel Industries Inc.——Itoco Inc.——CERo Therapeutics Holdings, Inc.——Virpax Pharmaceuticals, Inc.——Binovi Technologies Corp.——Key facts
CEORandall E. McCoy
SectorHealthcare
IndustryBiotechnology
HeadquartersLittle Falls, NJ
ExchangeOTC: RGIN
Employees3
IPO date2009-11-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.